Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 3
1994 7
1995 3
1996 3
1997 2
1998 6
1999 7
2000 14
2001 5
2002 14
2003 19
2004 18
2005 16
2006 11
2007 7
2008 11
2009 1
2010 4
2011 4
2012 1
2013 5
2014 3
2015 2
2016 1
2019 1
2020 2
2021 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Results by year

Filters applied: . Clear all
Page 1
Rubitecan.
Clark JW. Clark JW. Expert Opin Investig Drugs. 2006 Jan;15(1):71-9. doi: 10.1517/13543784.15.1.71. Expert Opin Investig Drugs. 2006. PMID: 16370935 Review.
In addition to issues of lactone ring stability at physiological pH (true for all of the camptothecin analogues), there is pharmacokinetic variability that has had to be dealt with during the development of rubitecan. Preclinically, rubitecan has shown activity agai …
In addition to issues of lactone ring stability at physiological pH (true for all of the camptothecin analogues), there is pharmacokinetic v …
Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy.
Patel H, Stoller R, Auber M, Potter D, Cai C, Zamboni W, Kiefer G, Matin K, Schmotzer A, Ramanathan RK. Patel H, et al. Invest New Drugs. 2006 Jul;24(4):359-63. doi: 10.1007/s10637-006-6451-2. Invest New Drugs. 2006. PMID: 16525767 Clinical Trial.
BACKGROUND: Rubitecan (RFS-2000, 9NC, Orathecin) is an orally bioavailable camptothecin analogue, with evidence of preclinical activity in colon cancer cell lines. We evaluated oral rubitecan (5 days on, 2 days rest per week) on a continuous schedule, in patients wi …
BACKGROUND: Rubitecan (RFS-2000, 9NC, Orathecin) is an orally bioavailable camptothecin analogue, with evidence of preclinical activi …
Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan).
Giovanella BC, Stehlin JS, Hinz HR, Kozielski AJ, Harris NJ, Vardeman DM. Giovanella BC, et al. Int J Oncol. 2002 Jan;20(1):81-8. Int J Oncol. 2002. PMID: 11743646
Using maximum tolerated multiple doses, the sensitivity of human cancer xenografts in nude mice to Rubitecan was determined. MTD of Rubitecan in mice for multiple doses intrastomach at the schedule of 5+,2- was 1 mg/kg/day. ...Treatment of human cancer xenografts in …
Using maximum tolerated multiple doses, the sensitivity of human cancer xenografts in nude mice to Rubitecan was determined. MTD of …
Phase II trial of oral rubitecan in previously treated pancreatic cancer patients.
Burris HA 3rd, Rivkin S, Reynolds R, Harris J, Wax A, Gerstein H, Mettinger KL, Staddon A. Burris HA 3rd, et al. Oncologist. 2005 Mar;10(3):183-90. doi: 10.1634/theoncologist.10-3-183. Oncologist. 2005. PMID: 15793221 Free article. Clinical Trial.
This phase II, open-label trial was developed to assess the safety and efficacy of rubitecan in patients with locally advanced or metastatic pancreatic cancer refractory to conventional chemotherapy. ...The overall risk-benefit profile of oral rubitecan appears prom …
This phase II, open-label trial was developed to assess the safety and efficacy of rubitecan in patients with locally advanced or met …
Phase II study of rubitecan in recurrent or metastatic head and neck cancer.
Caponigro F, Cartenì G, Droz JP, Milano A, Davis WB, Pollard P. Caponigro F, et al. Cancer Chemother Pharmacol. 2008 Jul;62(2):209-14. doi: 10.1007/s00280-007-0592-7. Epub 2007 Sep 19. Cancer Chemother Pharmacol. 2008. PMID: 17882418 Clinical Trial.
PURPOSE: Rubitecan is an oral camptothecin analogue that has shown activity against a broad spectrum of human tumor xenografts and has been tested in several diseases. ...The drug was also associated with grade 1-4 neutropenia, and with 1-3 thrombocytopenia. CONCLUSION: We …
PURPOSE: Rubitecan is an oral camptothecin analogue that has shown activity against a broad spectrum of human tumor xenografts and ha …
Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
[No authors listed] [No authors listed] Drugs R D. 2004;5(5):305-11. doi: 10.2165/00126839-200405050-00007. Drugs R D. 2004. PMID: 15357630
Rubitecan was isolated by the Stehlin Foundation in the US. SuperGen is currently awaiting regulatory approval in the US and the EU for rubitecan in the treatment of pancreatic cancer. ...In December 2002, SuperGen was granted US patent No. 6,482,830, covering its p …
Rubitecan was isolated by the Stehlin Foundation in the US. SuperGen is currently awaiting regulatory approval in the US and the EU f …
Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue.
Schöffski P, Herr A, Vermorken JB, Van den Brande J, Beijnen JH, Rosing H, Volk J, Ganser A, Adank S, Botma HJ, Wanders J. Schöffski P, et al. Eur J Cancer. 2002 Apr;38(6):807-13. doi: 10.1016/s0959-8049(02)00022-9. Eur J Cancer. 2002. PMID: 11937315 Clinical Trial.
All patients were evaluable for safety. The toxicity profile of rubitecan was generally mild to moderate, with sporadic cases of grade 4 toxicities (Common Toxicity Criteria (CTC) version 2.0) diarrhoea, leucopenia and neutropenia. ...Rubitecan is well tolerated, bu …
All patients were evaluable for safety. The toxicity profile of rubitecan was generally mild to moderate, with sporadic cases of grad …
Alternative administration of camptothecin analogues.
Glaberman U, Rabinowitz I, Verschraegen CF. Glaberman U, et al. Expert Opin Drug Deliv. 2005 Mar;2(2):323-33. doi: 10.1517/17425247.2.2.323. Expert Opin Drug Deliv. 2005. PMID: 16296757 Review.
In order to improve the therapeutic index of camptothecin (CPT) analogues, alternative administration of CPT analogues is being evaluated. Topotecan, irinotecan, rubitecan, lurtotecan and 9-aminocamptothecin have been administered orally with response rates equivalent to t …
In order to improve the therapeutic index of camptothecin (CPT) analogues, alternative administration of CPT analogues is being evaluated. T …
Phase I study of rubitecan and gemcitabine in patients with advanced malignancies.
Fracasso PM, Rader JS, Govindan R, Herzog TJ, Arquette MA, Denes A, Mutch DG, Picus J, Tan BR, Fears CL, Goodner SA, Sun SL. Fracasso PM, et al. Ann Oncol. 2002 Nov;13(11):1819-25. doi: 10.1093/annonc/mdf342. Ann Oncol. 2002. PMID: 12419757 Free article. Clinical Trial.
BACKGROUND: Rubitecan (9-nitrocamptothecin, 9-NC, Orathecin) and gemcitabine have single-agent activity in pancreatic and ovarian carcinoma. ...RESULTS: The MTD was defined as rubitecan 1 mg/m(2) administered orally days 1-5 and 8-12, and gemcitabine 1000 mg/m(2) ad …
BACKGROUND: Rubitecan (9-nitrocamptothecin, 9-NC, Orathecin) and gemcitabine have single-agent activity in pancreatic and ovarian car …
Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule.
Schoemaker NE, Mathôt RA, Schöffski P, Rosing H, Schellens JH, Beijnen JH. Schoemaker NE, et al. Cancer Chemother Pharmacol. 2002 Dec;50(6):514-7. doi: 10.1007/s00280-002-0516-5. Epub 2002 Nov 5. Cancer Chemother Pharmacol. 2002. PMID: 12451480 Clinical Trial.
PURPOSE: Our aim was to develop an optimal sampling strategy for the description of the pharmacokinetics of rubitecan and its active metabolite 9-aminocamptothecin (9-AC) for use in phase II/III studies with oral rubitecan administered in a daily times five schedule …
PURPOSE: Our aim was to develop an optimal sampling strategy for the description of the pharmacokinetics of rubitecan and its active …
163 results